Brahms GmbH
$101.8K 2 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Reapplix Inc.
Reapplix Inc. reported $101,738.03 across General Payments, Research, and Ownership to 318 physicians and teaching hospitals across 318 transactions.
- $101.7K Below-median payer
- All-tracks total
- 318 Above-median volume
- Transactions
- 318 Above-median reach
- Recipients
- +$41.1K
- General Payments vs PY2023
Reapplix Inc. reported $101,738.03 across all CMS Open Payments tracks (General + Research + Ownership) to 318 physicians and teaching hospitals in Program Year 2024 - ranking #1182 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $101,738.03, averaging $319.93 per recipient.
Reapplix Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
11/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer reapplix-inc Reapplix Inc.
$101.7K · #1182/1,925 · 0.0% industry · PY2024
- TOT $101.7K
- RANK #1182
- SHARE 0.0%
- TXN 318
- RCP 318
- CAT 3
- GEN $101.7K
- ΔGEN +$41.1K
- TOP1 49.9%
- PY 2024
Volume peers
Nearest volume peer: Brahms GmbH ($101.8K)
Reapplix Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Reapplix Inc.'s CMS-reported General Payments increased by $41.1K (+67.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: REAPPLIX INC.PY2023: REAPPLIX INC.PY2024: Reapplix Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $60,664.71
- PY2024
- $101,738.03
What the Data Shows for Reapplix Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Reapplix Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Compensation for Services Other Than Consulting" leads the 3-category general-payment breakdown below at $46.8K (46.0% of General Payments, 9 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Reapplix Inc. made 3 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $46.8K, 46.0% of General Payments.
How Reapplix Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $46.8K | 9 | 46.0% |
| Compensation for Faculty or Speaker (Medical Education) | $38.9K | 6 | 38.3% |
| Food and Beverage | $16.1K | 303 | 15.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $88,251.10 (86.7%) of $101,738.03 in this company's General Payments records across 203 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Reapplix Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Tyson E Green
$50,741.08 across 22 reported transactions
- 2
James C Lin
$20,463.50 across 15 reported transactions
- 3
Ashley Rose Sonney
$9,971.60 across 2 reported transactions
- 4
Kara Springfield Couch
$6,557.41 across 6 reported transactions
- 5
Marcus Clay Stokes
$517.51 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Reapplix Inc. ranks #1182 of 1,925 by total payments (bottom 39% by spend) but is notably more concentrated than that alone would suggest -- #564 of 1,838 by HHI (top 31% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Delphinus Medical Technologies, Inc. : $435.0K total payments, HHI 3070
- Perfuze Limited : $36.4K total payments, HHI 3056
- Medicaroid, Inc. : $3.1K total payments, HHI 3056
- Bard Access Systems, Inc. : $278.7K total payments, HHI 3052
- Den-Mat Holdings, LLC : $35.9K total payments, HHI 3047
- Maxx Health Inc : $11.5K total payments, HHI 3036
- Reapplix Inc. (this company) : $101.7K total payments, HHI 3032
- McKesson Specialty Care Distribution, LLC : $271.93 total payments, HHI 3010
- Moon Surgical : $46.8K total payments, HHI 3007
- Elekta AB (publ) : $740.86 total payments, HHI 3002
- Ingeniumspine, LLC : $13.0K total payments, HHI 2996
- Lenoss Medical Inc : $18.6K total payments, HHI 2991
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Reapplix Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Reapplix Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Reapplix Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Shofu Dental Corp
$101.9K 106 recipients
Compare payment profiles
BioPro, Inc.
$101.9K 145 recipients
Compare payment profiles
Kowa Pharmaceuticals America, Inc.
$101.9K 5,883 recipients
Compare payment profiles
Forthright Medical - MT, LLC
$100.4K 51 recipients
Compare payment profiles
Longeviti Neuro Solutions LLC
$100.4K 65 recipients
Compare payment profiles
Put this to use
Reapplix Inc. ranks #1182 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Reapplix Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.